Royce Smaller-Companies Growth Fund FY 2025: What Worked

Impact · against what's priced in

The article provides a retrospective on fund performance rather than new catalysts. While it highlights positive operational trends for Impinj and Palvella, these updates reflect historical success and long-term potential likely already captured by the market.

PI+0.40

No priced-in read yet

In context

Impinj is diversifying its customer base and expanding its total addressable market, supported by a strong patent portfolio.

Read from the article alone

• pharmaceuticals
• PI
• clinical trials
• fda
• health care
• industrials
• materials
• patents

Search tags